GSK (NYSE: GSK) president reports ADS vesting and tax-related share sale

Rhea-AI Filing Summary

GSK plc reported a management share transaction involving President Maya Martinez-Davis. On February 13, 2026, performance share awards granted in 2020 under GSK’s 2017 Performance Share Plan vested, delivering 10,836.957 American Depositary Shares (ADS) at a price of $0.00 to the executive.

On the same date, 4,009.778 ADS were sold on the New York Stock Exchange at a price of $58.8509 per ADS to meet tax liabilities arising from the vesting. The remaining ADS from the award vesting continue to be held by the executive. These transactions reflect routine equity-based compensation and related tax settlement for a senior leader.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	The vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan following a voluntary 3-year deferral
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	10,836.957
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-13
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADS to meet tax liabilities on the vesting of awards granted in 2020 under the Company's 2017 Performance Share Plan following a voluntary 3-year deferral
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.8509	4,009.778
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-13
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 17, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that President Maya Martinez-Davis had performance share awards from 2020 vest, delivering 10,836.957 ADS, and sold 4,009.778 ADS on the NYSE to cover tax liabilities triggered by this vesting event.

How many GSK (GSK) ADS vested for Maya Martinez-Davis and at what price?

10,836.957 GSK American Depositary Shares vested for Maya Martinez-Davis at a price of $0.00. This reflects the delivery of shares under the 2017 Performance Share Plan, following a voluntary three-year deferral of awards granted in 2020.

How many GSK (GSK) ADS were sold to cover tax liabilities and at what price?

Maya Martinez-Davis sold 4,009.778 GSK ADS at $58.8509 per share. The sale occurred on the New York Stock Exchange specifically to meet tax liabilities arising from the vesting of performance share awards granted in 2020.

On what date did the reported GSK (GSK) transactions by Maya Martinez-Davis occur?

Both the vesting of awards and the related sale of ADS by Maya Martinez-Davis occurred on February 13, 2026. The vesting delivered shares under GSK’s 2017 Performance Share Plan, and the sale was executed to satisfy associated tax obligations.

What compensation plan was involved in the GSK (GSK) ADS vesting for Maya Martinez-Davis?

The vesting related to awards granted in 2020 under GSK’s 2017 Performance Share Plan. These awards vested after a voluntary three-year deferral period, resulting in the delivery of 10,836.957 American Depositary Shares to President Maya Martinez-Davis.

Where were the GSK (GSK) ADS sold by Maya Martinez-Davis to meet tax liabilities?

The 4,009.778 GSK ADS sold to meet tax liabilities were transacted on the New York Stock Exchange, identified as XNYS. This sale was linked directly to the vesting of performance share awards granted in 2020 under the company’s 2017 plan.